Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Under the PIPseq program, Columbia University researchers sequenced the exome, transcriptome, or a gene panel in tumors of 101 high-risk pediatric cancer patients.
A small study has found that two next-generation sequencing tests that examined the same cancers uncovered different genetic alterations.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The company reported $29.4 million in revenues for the quarter and a net loss of $31.3 million, while the number of clinical tests increased to 11,627.
Under the agreement, researchers can use Foundation Medicine's assays to select patients eligible for Sarah Cannon Research Institute's clinical studies.
Expression profiles of 1,900 B-cell acute lymphoblastic leukemia cases point to the presence of a subtype marked by rearrangements in transcription factor DUX4.
Additions to the company's portfolio in the last two years provide a broader footing for clinical NGS analysis and reporting workflows.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.